PENTIXAPHARM HOLDING N AG

Pentixapharm Holding AG is a clinical-stage biopharmaceutical company based in Berlin, Germany, founded in 2019. It develops radiopharmaceuticals focused on CXCR4-binding, peptide-based technology. Its pipeline includes PentixaFor (PT-001), a Gallium-68-based tracer for diagnosing and monitoring hematological and solid tumors, endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a Yttrium-90 and Lutetium-177-based therapeutic radiopharmaceutical for leukemia in Phase 1/2 study. The company also develops a diagnostic for functional adrenal tumors in Phase II study, anti-GlycoTarget antibodies for solid tumors, and PentixaFor as a diagnostic tool for primary hypertension in Phase III trial. Its oncology pipeline includes PT-00X, GT-00X, GT-001, GT-002, GT-005, and GT-008.